×
About 1,005 results

ALLMedicine™ Infantile Hemangioma Center

Research & Reviews  359 results

Hemangioma Endothelial Cells and Hemangioma Stem Cells in Infantile Hemangioma.
https://doi.org/10.1097/SAP.0000000000002835
Annals of Plastic Surgery; Sun Y, Qiu F et. al.

Jan 14th, 2022 - Hemangioma is one of the most common benign tumors in infants and young children. The 2 most important cells in the course of infantile hemangioma (IH) are hemangioma stem cells (HemSCs) and hemangioma endothelial cells (HemECs). Infantile hemangi...

Infantile Hemangioma: A Current Review.
https://doi.org/10.1097/MPH.0000000000002384
Journal of Pediatric Hematology/oncology; Pahl KS, McLean TW

Dec 31st, 2021 - Infantile hemangiomas (IHs) are common vascular lesions which are benign but can cause significant functional and cosmetic morbidity. Since the fortuitous discovery of propranolol being effective to treat IH over a decade ago, the therapy and prog...

Safety assessment of propranolol for infantile hemangioma: a study in an Asian population.
https://doi.org/10.1080/17512433.2022.2020638
Expert Review of Clinical Pharmacology; Yu L, Wei L et. al.

Dec 18th, 2021 - To evaluate the safety of initiating and maintaining propranolol therapy for infantile hemangioma (IH) and the safety of different doses. The retrospective analysis included 336 consecutive cases of infants with IH treated between January 2016 and...

Non-β-blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infanti...
https://doi.org/10.1172/JCI151109
The Journal of Clinical Investigation; Seebauer CT, Graus MS et. al.

Dec 8th, 2021 - Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(-) enantiomers: the R(+) enantiomer is largely devoid of β-blocker activity. We investigated the effect of R(+) enantiomers of propra...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  6 results

Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
https://clinicaltrials.gov/ct2/show/NCT02342275

Jan 20th, 2021 - Currently, propranolol is the preferred treatment for problematic proliferating infantile hemangiomas (IHs). Although propranolol is clearly efficacious, rare side effects, such as hypoglycemia, may be life-threatening. The possibility of proprano...

''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
https://clinicaltrials.gov/ct2/show/NCT04684667

Dec 24th, 2020 - Infantile hemangiomas (IH) are benign tumors of vascular endothelium.They are the most common tumors of infancy. They occur in about 4% of infants, though early studies were as high as 10%, probably due to the inclusion of other vascular lesions. ...

Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma
https://clinicaltrials.gov/ct2/show/NCT04288700

Feb 28th, 2020 - Infantile hemangiomas are the most common benign tumor of infancy, affecting up to 10% of the pediatric population with a higher incidence in female (3:1), preterm infants, and Caucasian population. The molecular mechanisms underlying pathogenesis...

suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS
https://clinicaltrials.gov/ct2/show/NCT02509468

Sep 18th, 2019 - Vascular anomalies include a heterogeneous group of disorders of newborns and children. While infantile hemangioma are common (10% of infants), generally not complicated and easily managed, the majority of other vascular anomalies are rare (<2% al...

Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma
https://clinicaltrials.gov/ct2/show/NCT01743885

Jun 1st, 2016 - There is no effective treatment for hemangioma regardless of immediate severity. That is in this respect a orphan disease. These hemangiomas, sometimes large, will have a phase of proliferation of several months (very scary for parents) and regres...

see more →

News  31 results

Study Finds Nadolol Noninferior to Propranolol for Infantile Hemangiomas
https://www.medscape.com/viewarticle/963664

Nov 25th, 2021 - Pediatric dermatologists who treat infantile hemangioma (IH) can consider nadolol as a noninferior — and possibly a better — alternative to the standard treatment propranolol, according to a study published in JAMA Pediatrics. "In our experience, ...

The case for molecular classification of vascular anomalies presented
https://www.mdedge.com/dermatology/article/240067/pediatrics/case-molecular-classification-vascular-anomalies-presented
Doug Brunk

May 13th, 2021 - Emerging data suggest that molecular classification of vascular anomalies can improve prognostication and treatment for babies born with these malformations, according to Beth Drolet, MD. “We now know that 75%-80% of vascular malformations have ge.

Infantile Hemangiomas: Accurate Diagnosis Is Crucial
https://www.medscape.com/viewarticle/947467

Mar 15th, 2021 - The first rule about infantile hemangiomas: Make sure they're actually infantile hemangiomas, a pediatric dermatologist urged colleagues. Then watch patients closely, refer to specialists when appropriate, and consider propranolol in complicated o...

Management of Infantile Hemangiomas Clinical Practice Guidelines (2019)
https://reference.medscape.com/viewarticle/908544

Feb 6th, 2019 - The guidelines on the management of infantile hemangioma were released on December 24, 2018, by the AAP.[1,2] Five indications for early treatment of problematic infantile hemangiomas (IHs) include the following: Life-threatening lesions, such as ...

AAP infantile hemangioma guideline should empower primary care clinicians
https://www.mdedge.com/pediatrics/article/192799/dermatology/aap-infantile-hemangioma-guideline-should-empower-primary-care
Jill D. Pivovarov

Jan 16th, 2019 - The American Academy of Pediatrics has issued its first clinical practice guideline on infantile hemangiomas (IHs), given the dramatic increase in information available over the past decade. The aim in providing an evidence-based approach to evalu.

see more →

Patient Education  4 results see all →